Sikic D, Meidenbauer N, Lieb V, Keck B (2016)
Publication Type: Journal article
Publication year: 2016
Book Volume: 55
Pages Range: 952-5
Journal Issue: 7
DOI: 10.1007/s00120-016-0089-2
Tyrosine kinase inhibitors like sunitinib, sorafenib, pazopanib or axintinib are regarded the standard of care in the systemic therapy of metastatic renal cell carcinoma. However, the many side effects associated with this therapy pose challenges for the treating physician and the patient. This review offers an overview of the classification and the treatment of hypertension, which is one of the major side effects induced by all tyrosine kinase inhibitors, in order to improve treatment efficacy and patient compliance.
APA:
Sikic, D., Meidenbauer, N., Lieb, V., & Keck, B. (2016). Side effect management of tyrosine kinase inhibitors in urology : Hypertension. Urologe, 55(7), 952-5. https://doi.org/10.1007/s00120-016-0089-2
MLA:
Sikic, D., et al. "Side effect management of tyrosine kinase inhibitors in urology : Hypertension." Urologe 55.7 (2016): 952-5.
BibTeX: Download